

## AMOÉBA: final stages of development of 100% biocontrol plant in Cavailon

**Chassieu (France), September 22<sup>th</sup>, 2023 - 18h00 - AMOÉBA (FR0011051598 – ALMIB)** an industrial biotech in pre-commercialization\* specialized in the treatment of microbiological risk, developing a biocontrol agent for the treatment of plants in agriculture and a biological biocide for the treatment of industrial water, confirms the progress of its project for a production site dedicated to biocontrol applications, and announces the signing of the deed of purchase for the land to be used for the plant in Cavailon.



In February 2023, Amoéba submitted the building permit for its 100% biocontrol plant in Cavailon. In line with the project's timetable, the building permit was granted based on a project file presenting solid commitments to respect biodiversity and employees, enabling Amoéba to see its project validated on June 12, 2023, after three months of appraisal. The signing of the deed of sale, i.e. the final purchase of the land, is scheduled for September 26. This period also coincides with the end of the third-party recovery phase. Once these final stages have been completed, work should start in the 4th quarter of 2023.

The USIBIAM (Usine Biocontrôle Amoéba) project is the concrete expression of Amoéba's move into the industrialization phase, with a view to marketing its biocontrol solutions in early 2025. This major industrial project, expected to cost around €45 million over the period 2023-2025 (€23 million in capital expenditure and €22 million in operating expenses), is already being supported by BPI France to the amount of €5.9 million as part of the France 2030 program. Amoéba has also announced a €9 million financing in the form of simple bonds with the Swiss company Nice & Green. Amoeba continues to seek for additional funding.

Full details of Amoéba's industrial project can be found on the company's website: <https://amoeba-nature.com/projet-industriel/>

## **About AMOÉBA:**

Amoéba's ambition is to become a major player in the treatment of microbiological risk in the water, plant protection and health sectors. Based on the natural properties of the amoeba *Willaertia magna* C2c Maky, our biological solution is a viable alternative to the chemical products widely used in the industry today. Amoeba is currently focused on the closed system industrial cooling tower market in the United States estimated at €200 million (1) and on the global biocontrol market for plant protection estimated at €3 billion (2), out of a global market for chemical fungicides estimated at €21 billion (3). The commercialization of the associated biocides and phytosanitary products is subject to local regulatory approvals.

*\*At the end of 2022, Amoeba obtained approval of its active substance for biocidal use in closed cooling system and for biocontrol use in the United States. The substance has also been recommended for biocontrol use in Europe by the Austrian authority in the same year. The company is currently in a pre-commercialization phase for biocidal and plant protection applications and is expected to market its products by 2025. Founded in 2010 and based in Chassieu (Lyon, France), Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. For more information, please visit [www.amoeba-nature.com](http://www.amoeba-nature.com).*

(1): Amoéba data


(2): IBMA data

(3): Amoeba data

## **Contacts:**

### **Amoéba**

Jean-François DOUCET  
CFO


 +33 4 26 69 16 00

 [v.filiatre@amoeba-nature.com](mailto:v.filiatre@amoeba-nature.com)

### **Calyptus**

Investor & Press Relations

Nicolas HELIN / Mathieu CALLEUX

 +33 1 53 65 37 90 /91

 [amoeba@calyptus.net](mailto:amoeba@calyptus.net)

## **Disclaimer**

*This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 18, 2023 under number D23-0296 and available on the AMOÉBA website ([www.amoeba-nature.com](http://www.amoeba-nature.com)). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of AMOEBA to be materially different from such forward-looking statements.*